Altimmune, Inc. (NASDAQ:ALT) Receives $15.71 Consensus PT from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $15.7143.

Several equities analysts have recently weighed in on the stock. Leerink Partners assumed coverage on shares of Altimmune in a research report on Monday, June 22nd. They issued an “outperform” rating and a $10.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Altimmune in a research note on Wednesday, June 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target (down from $25.00) on shares of Altimmune in a report on Monday, May 18th. Wall Street Zen raised shares of Altimmune from a “strong sell” rating to a “sell” rating in a report on Saturday, June 27th. Finally, Citizens Jmp reduced their price objective on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a report on Thursday, May 14th.

Institutional Trading of Altimmune

Institutional investors have recently added to or reduced their stakes in the company. Rockefeller Capital Management L.P. boosted its position in shares of Altimmune by 79,838.9% in the fourth quarter. Rockefeller Capital Management L.P. now owns 43,167 shares of the company’s stock valued at $156,000 after acquiring an additional 43,113 shares during the period. Leonteq Securities AG increased its position in Altimmune by 6,400.0% during the first quarter. Leonteq Securities AG now owns 65,000 shares of the company’s stock worth $200,000 after acquiring an additional 64,000 shares during the period. North Star Investment Management Corp. raised its stake in Altimmune by 112.5% in the 1st quarter. North Star Investment Management Corp. now owns 17,000 shares of the company’s stock worth $52,000 after purchasing an additional 9,000 shares in the last quarter. Wealth Effects LLC raised its stake in Altimmune by 18.1% in the 1st quarter. Wealth Effects LLC now owns 131,950 shares of the company’s stock worth $406,000 after purchasing an additional 20,200 shares in the last quarter. Finally, AXQ Capital LP boosted its holdings in Altimmune by 25.8% in the 4th quarter. AXQ Capital LP now owns 25,701 shares of the company’s stock valued at $93,000 after purchasing an additional 5,266 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Altimmune Stock Performance

ALT opened at $2.85 on Friday. Altimmune has a 12-month low of $2.56 and a 12-month high of $6.44. The stock has a market cap of $554.24 million, a price-to-earnings ratio of -3.06 and a beta of 0.25. The business has a 50 day moving average of $2.90 and a 200-day moving average of $3.57. The company has a quick ratio of 29.56, a current ratio of 29.56 and a debt-to-equity ratio of 0.12.

Altimmune (NASDAQ:ALT) last posted its earnings results on Wednesday, May 13th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. On average, equities research analysts expect that Altimmune will post -0.64 earnings per share for the current year.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.